{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:08:11Z","timestamp":1793909291019,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200745"],"award-info":[{"award-number":["32200745"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Messenger RNA (mRNA)-based transient expression of chimeric antigen receptors (CARs) results in optimal safety profiles and provides promising opportunities to address existing challenges associated with viral vector-based CAR-T-cell therapies and to meet emerging medical needs for noncancerous indications. Conventional linear mRNAs, however, are intrinsically unstable and typically support short-lived protein expression, which can constrain therapeutic activity. Here, we engineered a high-efficiency permuted intron exon (PIE) platform to synthesize scarless circular mRNAs (cmRNAs) that drive robust CAR expression with extended durability. The scarless design avoids extraneous junction sequences, streamlining manufacturability and potentially reducing innate immune sensing. Compared with linear mRNAs, cmRNAs significantly increased both the magnitude and duration of anti-CD19 CAR and anti-GPRC5D CAR expression in primary human T cells. Functionally, cmRNA-based CAR-T cells elicited superior antitumor efficacy over their linear mRNA counterparts, as demonstrated by parallel lines of evidence, including in vitro antigen-specific cytotoxicity, cytokine release, and transcriptomics patterns consistent with sustained activation and absence of exhaustion signatures, as well as in vivo models demonstrating tumor elimination and prolonged survival benefits. Collectively, these findings position cmRNA as a next-generation mRNA modality for potent and controllable CAR expression, thereby providing a robust platform to unleash the full potential of mRNA technologies in cellular immunotherapy and precision medicine.<\/jats:p>","DOI":"10.1038\/s41392-025-02512-4","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:01:53Z","timestamp":1766448113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy"],"prefix":"10.1038","volume":"10","author":[{"given":"Qinchao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaicheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-5550","authenticated-orcid":false,"given":"Xuyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2512_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"2512_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"2512_CR3","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"2512_CR4","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187, 4890\u20134904 (2024).","journal-title":"Cell"},{"key":"2512_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau, T. et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403, 1627\u20131630 (2024).","journal-title":"Lancet"},{"key":"2512_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"2512_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"2512_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","volume":"15","author":"D Yang","year":"2023","unstructured":"Yang, D. et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci. Transl. Med. 15, eadd1951 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2512_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","volume":"4","author":"C Amor","year":"2024","unstructured":"Amor, C. et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat. Aging 4, 336\u2013349 (2024).","journal-title":"Nat. Aging"},{"key":"2512_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2512_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2512_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1001\/jama.2024.1011","volume":"331","author":"M Suran","year":"2024","unstructured":"Suran, M. FDA adds boxed warning to CAR T-cell therapies, but says benefits outweigh risks of secondary cancers. JAMA 331, 818\u2013820 (2024).","journal-title":"JAMA"},{"key":"2512_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"2512_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584\u2013586 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2512_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"2512_CR16","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"2512_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR-T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2512_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609, 369\u2013374 (2022).","journal-title":"Nature"},{"key":"2512_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687\u2013696 (2023).","journal-title":"Nature"},{"key":"2512_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S. & Stephan, M. T. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020).","journal-title":"Nat. Commun."},{"key":"2512_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","volume":"42","author":"J Wu","year":"2024","unstructured":"Wu, J., Wu, W., Zhou, B. & Li, B. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol. 42, 228\u2013240 (2024).","journal-title":"Trends Biotechnol."},{"key":"2512_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2512_CR23","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192\u20131204 (2024).","journal-title":"Lancet"},{"key":"2512_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short, L., Holt, R. A., Cullis, P. R. & Evgin, L. Direct in vivo CAR T cell engineering. Trends Pharmacol. Sci. 45, 406\u2013418 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"2512_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung, J. B. et al. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat. Rev. Immunol. 24, 830\u2013845 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2512_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1089\/hum.2011.070","volume":"22","author":"DM Barrett","year":"2011","unstructured":"Barrett, D. M. et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 22, 1575\u20131586 (2011).","journal-title":"Hum. Gene Ther."},{"key":"2512_CR27","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol. Ther. 29, 3293\u20133304 (2021).","journal-title":"Mol. Ther."},{"key":"2512_CR28","doi-asserted-by":"publisher","first-page":"e004450","DOI":"10.1136\/jitc-2021-004450","volume":"10","author":"JB Foster","year":"2022","unstructured":"Foster, J. B. et al. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J. Immunother. Cancer 10, e004450 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2512_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2319856121","volume":"121","author":"CM Tilsed","year":"2024","unstructured":"Tilsed, C. M. et al. IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation. Proc. Natl Acad. Sci. USA 121, e2319856121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2512_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112\u2013120 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2512_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155, 29\u201332 (2018).","journal-title":"Gastroenterology"},{"key":"2512_CR32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","volume":"3","author":"PD Shah","year":"2023","unstructured":"Shah, P. D. et al. Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res. Commun. 3, 821\u2013829 (2023).","journal-title":"Cancer Res. Commun."},{"key":"2512_CR33","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu, C. X. & Chen, L. L. Circular RNAs: characterization, cellular roles, and applications. Cell 185, 2016\u20132034 (2022).","journal-title":"Cell"},{"key":"2512_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","volume":"23","author":"M Metkar","year":"2024","unstructured":"Metkar, M., Pepin, C. S. & Moore, M. J. Tailor made: the art of therapeutic mRNA design. Nat. Rev. Drug. Discov. 23, 67\u201383 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2512_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).","journal-title":"Nat. Commun."},{"key":"2512_CR36","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","volume":"74","author":"RA Wesselhoeft","year":"2019","unstructured":"Wesselhoeft, R. A. et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol. Cell. 74, 508\u2013520.e4 (2019).","journal-title":"Mol. Cell."},{"key":"2512_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"R Chen","year":"2023","unstructured":"Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262\u2013272 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2512_CR38","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s12276-024-01251-w","volume":"56","author":"SW Choi","year":"2024","unstructured":"Choi, S. W. & Nam, J. W. Optimal design of synthetic circular RNAs. Exp. Mol. Med. 56, 1281\u20131292 (2024).","journal-title":"Exp. Mol. Med."},{"key":"2512_CR39","doi-asserted-by":"publisher","first-page":"9253","DOI":"10.1093\/nar\/gky796","volume":"46","author":"Y Gholamalipour","year":"2018","unstructured":"Gholamalipour, Y., Karunanayake Mudiyanselage, A. & Martin, C. T. 3\u2019 end additions by T7 RNA polymerase are RNA self-templated, distributive and diverse in character-RNA-Seq analyses. Nucleic Acids Res. 46, 9253\u20139263 (2018).","journal-title":"Nucleic Acids Res."},{"key":"2512_CR40","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41587-024-02204-4","volume":"43","author":"SK Guo","year":"2025","unstructured":"Guo, S. K. et al. Therapeutic application of circular RNA aptamers in a mouse model of psoriasis. Nat. Biotechnol. 43, 236\u2013246 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2512_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.molcel.2021.11.019","volume":"82","author":"CX Liu","year":"2022","unstructured":"Liu, C. X. et al. RNA circles with minimized immunogenicity as potent PKR inhibitors. Mol. Cell 82, 420\u2013434.e6 (2022).","journal-title":"Mol. Cell"},{"key":"2512_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","volume":"76","author":"YG Chen","year":"2019","unstructured":"Chen, Y. G. et al. N6-Methyladenosine modification controls circular RNA immunity. Mol. Cell 76, 96\u2013109.e9 (2019).","journal-title":"Mol. Cell"},{"key":"2512_CR43","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41587-022-01530-9","volume":"40","author":"M Eisenstein","year":"2022","unstructured":"Eisenstein, M., Garber, K., Landhuis, E. & DeFrancesco, L. Nature Biotechnology\u2019s academic spinouts 2021. Nat. Biotechnol. 40, 1551\u20131562 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2512_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.omtn.2023.07.034","volume":"33","author":"KH Lee","year":"2023","unstructured":"Lee, K. H. et al. Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using Tetrahymena group I intron ribozyme. Mol. Ther. Nucleic Acids 33, 587\u2013598 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2512_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad554","volume":"51","author":"J Cui","year":"2023","unstructured":"Cui, J. et al. A precise and efficient circular RNA synthesis system based on a ribozyme derived from Tetrahymena thermophila. Nucleic Acids Res. 51, e78 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2512_CR46","doi-asserted-by":"publisher","first-page":"1068625","DOI":"10.3389\/fimmu.2023.1068625","volume":"14","author":"A Niu","year":"2023","unstructured":"Niu, A. et al. Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection. Front. Immunol. 14, 1068625 (2023).","journal-title":"Front. Immunol."},{"key":"2512_CR47","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","volume":"29","author":"ND Anderson","year":"2023","unstructured":"Anderson, N. D. et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nat. Med. 29, 1700\u20131709 (2023).","journal-title":"Nat. Med."},{"key":"2512_CR48","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"2512_CR49","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s43018-024-00768-3","volume":"5","author":"A Rezvan","year":"2024","unstructured":"Rezvan, A. et al. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat. Cancer 5, 1010\u20131023 (2024).","journal-title":"Nat. Cancer"},{"key":"2512_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400024","volume":"11","author":"Z Zhu","year":"2024","unstructured":"Zhu, Z. et al. mRNA-engineered CD5-CAR-\u03b3\u03b4TCD5- cells for the immunotherapy of T-cell acute lymphoblastic leukemia. Adv. Sci. 11, e2400024 (2024).","journal-title":"Adv. Sci."},{"key":"2512_CR51","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728\u20131744.e16 (2022).","journal-title":"Cell"},{"key":"2512_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2512_CR53","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"2512_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2512_CR55","doi-asserted-by":"publisher","first-page":"W168","DOI":"10.1093\/nar\/gkad393","volume":"51","author":"JE Evangelista","year":"2023","unstructured":"Evangelista, J. E. et al. Enrichr-KG: bridging enrichment analysis across multiple libraries. Nucleic Acids Res. 51, W168\u2013W179 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2512_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43656-7","volume":"14","author":"RHY Louie","year":"2023","unstructured":"Louie, R. H. Y. et al. CAR(+) and CAR(-) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies. Nat. Commun. 14, 7767 (2023).","journal-title":"Nat. Commun."},{"key":"2512_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.43","volume":"1","author":"Z Gu","year":"2022","unstructured":"Gu, Z. Complex heatmap visualization. Imeta 1, e43 (2022).","journal-title":"Imeta"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02512-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:01:54Z","timestamp":1766448114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02512-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2512"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02512-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.Z. is an employee of Byterna Therapeutics and the inventor on patents for Hi-Scarless-PIE and cmRNA-based CARs (PCT\/CN2024\/076385 and CN119662682A). No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"411"}}